Molecular Genetics Basis of Kidney Cancer In order to identify the genes that cause kidney cancer in order to develop molecular therapeutics for this disease, we have studied the inherited forms of cancer of the kidney. Kidney cancer occurs in both a hereditary and a sporadic (nonhereditary) form. There are five types of inherited kidney cancer: 1) von Hippel Lindau (VHL), the inherited form of clear cell renal carcinoma; 2) Hereditary Papillary Renal Carcinoma (HPRC), hereditary Type 1 kidney cancer, 3) Birt Hogg Dub (BHD), an inherited form of chromophobe renal carcinoma and 4) Hereditary Leiomyomatosis Renal Carcinoma (HLRCC), type 2 papillary renal carcinoma; and 5) Familial Renal Carcinoma (FRC). Individuals with the inherited form of kidney cancer associated with von Hippel Lindau are predisposed to develop tumors in the brain, spine, eyes, pancreas, adrenal gland and inner ear. By studying VHL families we were able to perform genetic linkage analysis to localize and subsequently identify the VHL gene on chromosome 3. We have identified the VHL gene mutation in the germline of 292/292 VHL kindreds and are currently studying genotype/phenotype relationships as well as evaluating minimally invasive forms of therapy for kidney and adrenal tumors in VHL. The VHL gene has been shown to be the gene for the hereditary form of renal carcinoma associated with von Hippel Lindau as well as the common form of sporadic (non-hereditary) kidney cancer (clear cell renal carcinoma). We described HPRC in 1994, found that the c-Met proto-oncogene, on chromosome 7, is the HPRC gene. Defects in the Met gene have been found in the germline of HPRC families and these mutations appear to account for most of the cases of inherited type 1 papillary renal carcinoma. We recently described another new type of inherited kidney cancer associated with Birt Hogg Dub Syndrome. These patients are at risk for the development of chromophobe renal cell carcinoma. We studied BHD kindreds and were able to localize and then identify the BHD gene on chromosome 17. We have described BHD mutations in 51/61 BHD kindreds. We have recently studied another inherited form of kidney cancer called Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC). These individuals are at risk for the development of a very aggressive form of type 2 papillary renal carcinoma. We have recently reported the identification of germline mutations of the fumarate hydratase gene (FH) in the germline of North American HLRCC kindreds and described how altration of the FH gene affects HIF1 and HIF2 levels in the HLRCC-associated kidney tumors. The identification of germline VHL, c-Met, BHD and FH mutations makes possible pre-symptomatic genetic testing for at-risk individuals in VHL, HPRC, BHD and HLRCC families and paves the way for additional studies to understand the pathology of these diseases, and for the design of effective new therapies targeted to the specific defects brought about by mutation of the these disease genes. We have recently demonstrated improved detection of germline mutations in the von Hippel Lindau disease tumor suppressor gene. We can now detect mutations in nearly 100% of families. We have additionally detected a new phenotype associated with complete deletion of the VHL gene. We are intensively studying the somatic events (genomic, cytogenetic) associated with the development of tumors in patients with different types of germline mutations. The ability to detect germline as well as somatic mutations of the VHL, Met, BHD and FH gene may provide substantial opportunity for improvements in the diagnosis of both hereditary as well as sporadic forms of kidney cancer. Finally, we are studying the genetic basis of Familial Renal Carcinoma (FRC). FRC is a term that describes the kidney that runs in families that are not part of previously described hereditary kidney cancer syndromes.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC006659-23
Application #
7292015
Study Section
(UOB)
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Sourbier, Carole; Ricketts, Christopher J; Matsumoto, Shingo et al. (2014) Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. Cancer Cell 26:840-850
Atkins, Michael B; Bukowski, Ronald M; Escudier, Bernard J et al. (2009) Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 115:2247-51
Linguraru, Marius George; Wang, Shijun; Shah, Furhawn et al. (2009) Computer-aided renal cancer quantification and classification from contrast-enhanced CT via histograms of curvature-related features. Conf Proc IEEE Eng Med Biol Soc 2009:6679-82
Linehan, W Marston (2009) Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol 27:3731-3
Beroukhim, Rameen; Brunet, Jean-Philippe; Di Napoli, Arianna et al. (2009) Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69:4674-81
Sudarshan, Sunil; Sourbier, Carole; Kong, Hye-Sik et al. (2009) Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 29:4080-90
Boris, Ronald; Proano, Miguel; Linehan, W Marston et al. (2009) Initial experience with robot assisted partial nephrectomy for multiple renal masses. J Urol 182:1280-6
Giubellino, Alessio; Linehan, W Marston; Bottaro, Donald P (2009) Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 9:785-93
Rosner, Inger; Bratslavsky, Gennady; Pinto, Peter A et al. (2009) The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 27:131-6
Linehan, W Marston; Pinto, Peter A; Bratslavsky, Gennady et al. (2009) Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115:2252-61

Showing the most recent 10 out of 113 publications